

Title: The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic

McKaylee M Robertson^{1,2} Saba A Qasmieh^{1,2}, Sarah G Kulkarni¹, Chloe A Teasdale^{1,2}, Heidi Jones^{1,2}, Margaret McNairy^{1,3}, Luisa N. Borrell², and Denis Nash^{1,2}

1. Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); New York, NY, USA
2. Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York, NY, USA
3. Center for Global Health and Division of General Internal Medicine, Weill Cornell Medicine, New York, NY, USA

Correspondence to: Denis Nash, PhD, MPH, Institute of Implementation Science in Population Health, City University of New York, New York, NY. Email: denis.nash@sph.cuny.edu

Abstract

Objectives: To characterize prevalence and impact of long COVID.

Methods: We conducted a population-representative survey, June 30-July 2, 2022, of a random sample of 3,042 United States adults. Using questions developed by the United Kingdom's Office of National Statistics, we estimated the prevalence by sociodemographics, adjusting for gender and age.

Results: An estimated 7.3% (95% CI: 6.1-8.5%) of all respondents reported long COVID, approximately 18,533,864 adults. One-quarter (25.3% [18.2-32.4%]) of respondents with long COVID reported their day-to-day activities were impacted 'a lot' and 28.9% had SARS-CoV-2 infection >12 months ago. The prevalence of long COVID was higher among respondents who were female (aPR: 1.84 [1.40-2.42]), had comorbidities (aPR: 1.55 [1.19-2.00]) or were not (versus were) boosted (aPR: 1.67 [1.19-2.34]) or not vaccinated (versus boosted) (aPR: 1.41 (1.05-1.91)).

Conclusions: We observed a high burden of long COVID and substantial variability in prevalence of SARS-CoV-2. Population-based surveys are an important surveillance tool and supplement to ongoing efforts to monitor long COVID.

Words: 159

1 INTRODUCTION

2 Post-COVID conditions (PCC) or “long COVID” consists of new, recurring or ongoing
3 symptoms or clinical findings four or more weeks after SARS-CoV-2 infection, and may
4 potentially affect millions of the 58% of Americans estimated to have been infected with
5 COVID since March of 2020.¹⁻⁴ Estimates of the prevalence of long COVID vary widely
6 based on study design, population, and case definition.⁵ The United States (US)
7 Centers for Disease Control and Prevention estimated that one in five people with *prior*
8 COVID are currently experiencing long COVID as of June 2022⁶. In the US,
9 assessments of long COVID prevalence have largely been derived from sources that
10 are not population-representative: cross-sectional convenience samples or electronic
11 health record and cohort analyses.^{2,3,6-8} Routinely updated, population-representative
12 estimates of long COVID prevalence are available in the United Kingdom (UK)⁹ where
13 the Office of National Statistics (ONS) assesses long-COVID symptoms approximately
14 every four weeks. Over the 4-week period ending June 4, 2022, an estimated 2 million
15 (2.8%) of the total UK population aged 2 years or older had long COVID.⁹
16
17 Little is known about risk factors for long COVID and the impact of long COVID on
18 activities of daily living. Knowledge gaps include who is most vulnerable and the extent
19 to which vaccines and boosters may be protective. In data from the US and Europe,
20 long COVID prevalence following SARS-CoV-2 infection appears to be consistently
21 higher among women and among people with multiple chronic conditions.^{5,10-13}
22 However, beyond female sex and presence of chronic conditions, data on risk factors
23 vary, likely due to differences in a) study design, often lacking COVID-free or other

24 control/comparison groups, b) population, often conducted among hospitalized or
25 healthcare seeking populations, and/or c) case definition of long COVID.^{10–12,14,15}
26 Given that SARS-CoV-2 vaccines, especially without boosters, are increasingly less
27 effective at providing sterilizing immunity against omicron variants^{16–20} and that half of
28 the population is estimated to have had COVID at least once⁴, understanding the
29 prevalence of long COVID by vaccination status is critical. Limited data suggest a
30 modest reduction in long COVID risk among vaccinated compared with unvaccinated or
31 COVID-naive people and among unvaccinated people who went on to receive a
32 vaccination versus people who did not.^{21,22}

33

34 Our objective was to characterize the prevalence and risk factors of long COVID and
35 the impact of long COVID on daily living in a population representative sample of US
36 adults (aged 18+ years).

37

38 **METHODS**

39 *Study sample.* We conducted a probability-based, cross-sectional survey, in English
40 and Spanish, between June 30 and July 2, 2022, of 3,042 adults living in the United
41 States (US). Two stratified proportionate random population-based samples of potential
42 participants were drawn from a sampling frame of 105,469,157 mobile numbers and
43 from a frame 60,126,257 landlines. To help ensure representativeness, a sample from a
44 National opt-in Online Panel was also drawn. In the final sample, 62% of respondents
45 were recruited from landline, 32% from mobile and 6% from the online opt-in panel. To
46 create weights representative of the US-population 18 years or older, we used an

47 iterative weighting method, raking, to marginal proportions of race, ethnicity, age, self-
48 identified sex, and education by US region based on the 2020 US census²³. Our overall
49 response rate across all modalities was 7.2%, which is comparable with the Household
50 Pulse Survey (HPS), a national online survey sampling households from the Census
51 Master Address File with an email or cell phone number. Further details on the survey
52 design, sampling and weighting are provided in Appendix 1.

53

54 *Prevalence of ever having SARS-CoV-2 as of July 2022.* We assessed current and
55 previous SARS-CoV-2 infection status . Respondents with a current SARS-CoV-2
56 infection during the 14-days prior to the survey were identified based on the following
57 mutually exclusive, hierarchical case classification: 1) self-report of one or more positive
58 tests with a health care or testing provider; or 2) self-report of a positive test result
59 exclusively based on at-home rapid tests (i.e. those that were not followed up with
60 confirmatory diagnostic testing with a provider); or 3) self-report of COVID-like
61 symptoms AND a known epidemiologic link (close contact) to one or more laboratory
62 confirmed or probable (symptomatic) SARS-CoV-2 case(s)²⁴ in a respondent who
63 reported never testing or only testing negative during the study period. To assess
64 previous infections we asked all participants “Prior to June 15th 2022, did you ever have
65 COVID-19 infection, either diagnosed by a healthcare or testing provider, or based on a
66 positive at-home rapid test” and the most recent time they had COVID. The prevalence
67 of ever having COVID as of July 2022 was estimated as either meeting the case
68 definition for a current SARS-CoV-2 infection or responding affirmatively to having

69 SARS-CoV-2 infection prior to July 15th, 2022. The full survey questionnaire is in
70 Appendix 2.

71
72 *Long COVID Prevalence Estimation.* We used a question asked routinely by the ONS in
73 the UK to define and assess the burden of long COVID.²⁵ Participants who reported any
74 history of prior COVID were also asked “Would you describe yourself as having ‘long
75 COVID’, that is you experienced symptoms such as fatigue, difficulty concentrating,
76 shortness of breath more than 4 weeks after you first had COVID-19 that are not
77 explained by something else?” The prevalence of long COVID was estimated as the
78 proportion responding affirmatively. Respondents whose most recent SARS-CoV-2
79 infection was within the past month were classified as not having long COVID, to avoid
80 conflation of current symptoms with recent acute illness and to align with the UK
81 definition of long COVID, which was assessed more than four weeks from diagnosis.
82 We examined prevalence among all respondents, with or without prior COVID, to
83 compare with the UK ONS estimate.

84
85 *Reduced ability to carry out daily activities with long COVID.* We included a question
86 used by the UK ONS to assess the impact of long COVID on daily living. Participants
87 who reported that they had long COVID were asked “Does this reduce your ability to
88 carry-out day-to-day activities compared with the time before you had COVID-19?”
89 Response choices were on a likert 3-point scale of: “Yes, a lot; Yes, a little;” or “Not at
90 all”.

91

92 *Predictors of long COVID.* In addition to sociodemographic factors, we assessed other
93 potential predictors of long COVID status. To assess the presence or absence of
94 comorbidities, we asked “do you have any of the following conditions that could
95 increase the severity of COVID-19: cancer, diabetes, obesity, COPD or lung disease,
96 liver disease, heart disease, high blood pressure, a recent organ transplant, or an
97 immunodeficiency)?” The variable was dichotomized as Yes versus No/Do not know.
98 We collected information on whether, at the time of interview, participants were fully
99 vaccinated or boosted at least once. Respondents were classified as boosted, fully
100 vaccinated and not boosted, or not vaccinated/partially vaccinated.

101

102 *Statistical Analysis.* We estimated the prevalence of having ever had COVID as of July
103 2022, having long COVID and its impact to daily living by socio-demographic
104 characteristics, geographic region, current vaccination status, timing of most recent
105 infection, and presence of comorbidities. Survey weights were applied to generate
106 estimates of the proportion with COVID or long COVID along with 95% confidence
107 interval (95%CI). We used direct standardization to calculate age and sex-adjusted
108 prevalence estimates using the US 2020 census.²³

109

110 We used log-binomial models to obtain prevalence ratios (PR) and 95% confidence
111 intervals by sociodemographic characteristics or region, adjusting for age and gender
112 (aPR). As a sensitivity analysis of the age and gender-adjusted models, and given these
113 models were predictive not explanatory, we also used backward selection, keeping all
114 significant predictors. For impact of long COVID on daily living, among the subgroup

115 with long COVID, we compared “A lot” of reduced ability (versus a little and none). Due
116 to smaller sample sizes some sociodemographic factors were collapsed into larger
117 categories (e.g., ages 35-49). We used gender for adjustment since our survey
118 captured only gender. For standardization, we had to assume that reported gender was
119 reported sex.

120

121 The study protocol was approved by the Institutional Review Board at the City
122 University of New York (CUNY IRB 2022-0407).

123

124 **RESULTS**

125 *Prevalence of and risk factors for Long COVID in the general adult population.* An
126 estimated 7.3% (95% CI 6.1-8.5%) of all respondents reported currently having long
127 COVID as of July 2, 2022, which corresponds to approximately 18,533,864 US adults
128 (Table 1). The standardized prevalence of long COVID was highest among respondents
129 who were aged 25-34 (10.0% [6.8-14.6%]), 35-44 (9.0% [6.1-13.1%]), female (9.4%
130 [7.7-11.6%]), White non Hispanic (NH) (8.7% [7.1-10.7%]), had a household income of
131 \$20,001-60,000 (8.8% [6.6-11.6%]) or 60,001-100,000 (8.5% [6.1-11.7%]), were
132 employed (8.9% (7.2-11.0%)), or reported having comorbidities (10.3% [7.8-13.4%])
133 (Table 1). The standardized prevalence of long COVID was lowest among respondents
134 who were youngest (18-24 years: 4.4% [1.8-10.0%]), oldest (65+ years: 4.3% (3.0-
135 5.8%)), male (5.0% [3.8-6.5%]), Black NH (5.2% [2.9-9.3%]), Hispanic (5.7% [2.9-
136 11.0%]), Asian/Pacific Islander (API) NH (1.4% [0.3-5.9%]), uninsured (4.3% [2.7-6.8%])
137 or currently vaccinated and boosted (5.8% [4.4-7.7%]).

138 In age and gender-adjusted models, there was a higher prevalence of long COVID
139 among respondents who were females (versus males) (aPR: 1.84 [1.40-2.42]), with
140 (versus without) comorbidities (aPR: 1.55 [1.19-2.00]), who were employed (versus
141 unemployed) (aPR: 1.34 [1.02-1.76]), who were insured (versus not or unknown) (aPR:
142 1.93 [1.33-2.80]), who were not (versus were) boosted (aPR: 1.67 [1.19-2.34]), or who
143 were not vaccinated (versus boosted) (aPR: 1.41 (1.05-1.91)). We observed a lower
144 prevalence of long COVID among respondents who were aged 18-24 (versus 25-34
145 years)(aPR: 0.50 [0.30-0.84]), aged 65+ (versus 25-34 years) (aPR: 0.43 [0.27-0.66]),
146 were Black NH (versus White NH) (aPR: 0.60 [0.38- 0.96]), were Hispanic (versus
147 White NH) (aPR: 0.57 [0.37-0.89]), or were API NH (versus White NH) (aPR: 0.44 [0.21-
148 0.93]). In the backward selection model, which included age, gender, race/ethnicity,
149 current vaccination status, presence of comorbidities or current insurance status, the
150 effect sizes remained the same or increased in strength (further from null)
151 (Supplemental Table 1).

152 *The impact of long COVID on daily activities.* The proportion of respondents with long
153 COVID reporting a reduced ability to carry out daily activities and associations of this
154 reporting with individual characteristics are shown in Table 2. Due to small sample
155 sizes, 95% confidence intervals were wide. One-quarter (25.3% [18.2-32.4%]), an
156 estimated 4.7 million adults, reported their daily activities were impacted ‘a lot’, and
157 reporting of ‘a lot’ of impact was more common among respondents who were aged 50+
158 (33.6% [23.9-43.2%]), were White NH (33.6% [23.9-43.2%]), had a household income
159 <60K (32.9% [21.4-44.4%]), or were unemployed (36.3% [24.1-48.6%]). In age- and
160 gender-adjusted models, we observed a significantly higher proportion reporting ‘a lot’

161 of impact on ability of daily activities among respondents with a household income <60K
162 (versus 60K+) (aPR: 2.22 [1.31-3.78]), and a lower proportion reporting ‘a lot’ of
163 reduced ability of daily activities among employed (versus unemployed) respondents
164 (aPR: 0.48 [0.29-0.79]).

165 Among those with long COVID, less than half (44%) reported their most recent SARS-
166 CoV-2 infection within the past 1-6 months ago, 27% reported within 6-12 months, and
167 29% >12 months ago. The impact on daily activities decreased modestly with time since
168 the most recent SARS-CoV-2 infection. The proportion reporting ‘a lot’ of impact on
169 daily living was highest among respondents with a SARS-CoV-2 infection within the
170 past 1-6 months (30.2% [18.5-41.8%]) followed by 6-12 months ago (24.2% [10.2-
171 38.1%]; aPR_{versus 1-6months}: 0.80 (0.47, 1.36)) and >12 months ago (18.9% [8.6-29.2%];
172 aPR_{versus 1-6months}: 0.52 [0.29-0.94]).

173 *Risk factors for ever having SARS-CoV-2 infection as of July 2022.* The prevalence of
174 ever having SARS-CoV-2 infection as of July 2022 was 52.7% (95% CI: 50.2-55.2%)
175 (Table 3). The age- and sex-standardized prevalence of ever having SARS-CoV-2
176 infection was greatest among the youngest age groups (25-34 years (66.0% [59.0-
177 72.0%]) and decreased with age. The standardized prevalence of ever having SARS-
178 CoV-2 infection was higher among males (56.8% [53.2-60.4%]) than among females
179 (47.8% [44.5-51.1%]) and among those with comorbidities (59.8 [55.8-63.7%]) than
180 those without comorbidities (48.4% [45.4-51.5%]). The standardized prevalence of ever
181 having a SARS-CoV-2 infection was 44.9% (37.9-52.1%) among Black NH
182 respondents, 53.2% (50.4-55.9%) among White NH, 60.7% (52.7-68.1%) among
183 Hispanic, and 34.6% (24.3-46.5%) among API respondents.

184 In adjusted models, women (versus men), respondents with comorbidities (versus not)
185 and Black NH and API (versus White NH) respondents were less likely to ever have had
186 COVID. Hispanic (versus White NH) respondents and respondents in older age groups
187 (versus 25-34 year olds) were more likely to have ever had COVID. Relative to
188 respondents who were vaccinated and boosted, respondents who were not boosted or
189 not vaccinated were slightly less likely to have ever had SARS-CoV-2 infection.
190 Vaccination status was eliminated from the backward selection model (Supplemental
191 Table 1).

192 **Discussion**

193 Using a population-representative sample of adults living in the US, we estimate that
194 approximately 18.5 million adults, 7.3% (95% CI: 6.1-8.5%) of the US adult population,
195 was experiencing long COVID (symptoms persisting for more than four weeks after the
196 most recent SARS-CoV-2 infection that were not explained by something else) during
197 the 2-week study period in June-July 2022. Our estimate of 7.3% is consistent with the
198 US Household Pulse Survey⁶, which estimated 7.5% [7.1-7.9%] of US adults were
199 currently experiencing long COVID. Distressingly, our estimate of prevalence (7.3%) is
200 more than twice that of the UK (2.8%) using the same survey questions.⁹ Of note, the
201 ONS estimates of long COVID are among all UK residents 2 years and older, whereas
202 we estimated long COVID prevalence among US residents 18 years and older. If *no*
203 children or adolescents aged 2-17 years have long COVID in the US, the proportion of
204 all US residents aged 2+ with long COVID would be approximately 5.4% (18 million
205 cases among 331.4 million people living in the United States).²⁶ This conservative
206 estimate of the proportion of US residents with active long COVID would remain nearly

207 twice that of the UK (5.4% versus 2.8%). The reasons for this difference are unclear, but
208 could include a lower cumulative incidence of all SARS-CoV-2 infections, including
209 repeat and breakthrough infections, in the UK, e.g. via earlier and higher uptake, as well
210 as better targeting of vaccines and boosters.²⁷ Other reasons could be a higher
211 prevalence of risk factors for long COVID (given a SARS-CoV-2 infection) in the US vs.
212 the UK (e.g., a higher prevalence of comorbidities²⁸). The causal and predisposing risk
213 factors for long COVID have not yet been fully elucidated. Understanding the reasons
214 for these differences could yield important insights about risk factors, making this an
215 important area for future research.

216

217 Long COVID has been associated with a broad range of non-specific symptoms that
218 can overlap with common medical conditions, which makes characterizing the burden of
219 long COVID difficult.⁷ CDC and NIH have established several initiatives to assess the
220 magnitude of long COVID in the US; however, a single surveillance system does not
221 exist, and assessment of long COVID incidence has largely been derived from non-
222 population representative sources.^{2,3,6-8} The national public health and medical
223 responses to managing the long term effects of COVID-19 will require understanding
224 long COVID burden, presentation and risk factors. Population-based surveys are an
225 important surveillance tool and supplement to the ongoing national efforts to monitor
226 long COVID.³

227

228 Identifying groups at higher risk for long COVID and understanding health disparities is
229 essential to managing the long term impacts of the COVID-19 pandemic. Many of the

230 existing studies on long COVID risk factors have been conducted in hospitalized or
231 care-seeking populations, which may overrepresent those with comorbidities. In our
232 study which was not restricted to people accessing medical care, we also observed that
233 female gender and presence of comorbidities were associated with a higher prevalence
234 of long COVID. Age has had an inconsistent association with long COVID in the
235 literature – with some studies finding higher prevalence of long COVID among the
236 oldest age groups.^{10,29} We observed a lower prevalence of long COVID among the
237 oldest (65+ years) age groups, which may be the result SARS-CoV-2 infection risk-
238 reduction behaviors, such as mask wearing of social distancing, higher uptake of
239 vaccines in older US residents, correction of bias from selecting care-engaged
240 populations, and higher rates of COVID mortality in this age group.⁸

241
242 Some differences were observed in the risk factors for long COVID versus those for
243 SARS-CoV-2 infection. While female respondents were less likely than male
244 respondents to have ever had SARS-CoV-2 infection, females were almost twice as
245 likely to currently have long COVID. Hispanic respondents were slightly more likely than
246 White NH respondents to have ever had SARS-CoV-2 infection but were substantially
247 less likely to have long COVID. Relative to respondents who were vaccinated and
248 boosted, respondents who were not boosted or not vaccinated were only slightly less
249 likely to have ever had SARS-CoV-2 infection, but they were much more likely to have
250 long COVID. Importantly, we did not capture timing or manufacturer of vaccination
251 relative to SARS-CoV-2 infection or long COVID, and the lack of temporal clarity in
252 these associations require that they be interpreted with caution. For female gender,

253 Hispanic ethnicity and vaccination, the differential risk in long COVID *may not* be due to
254 differences in infection risk and underscores the need for more detailed studies.

255

256 While our sample size was small for a detailed examination of those with long COVID,
257 approximately one in three reported their most recent SARS-CoV-2 infection was >12
258 months prior. We found a significant impact on daily living, which appeared to decrease
259 modestly with the time since the most recent infection. Respondents whose most recent
260 SARS-CoV-2 infection >12 months ago were less likely to report a significant impact on
261 current daily activities relative to respondents who were infected within the past 6
262 months. While the long-term prognosis and duration of long COVID remain unknown,
263 the natural history of long COVID may be gradual improvement with time for many who
264 have the condition.^{8,30}

265

266 Our study has other limitations worth noting. First, we measured SARS-CoV-2 infection
267 history over an extended period, which is subject to recall bias. Second, to avoid acute
268 COVID symptoms, we did not assess long COVID among respondents whose most
269 recent SARS-CoV-2 infection was within the past month. However, some of these
270 respondents may have long COVID from an earlier infection, which would result in an
271 underestimation of the current prevalence of long COVID. We also did not measure
272 treatment received for COVID, which may impact prevalence. Third, small sample sizes
273 among population subgroups, including people with long COVID, lowers the precision of
274 estimates across respondent characteristics. Fourth, we are unable to account for non-
275 response bias. If people who have COVID or long COVID were more likely to complete

276 the survey, estimates may be inflated. However, our long COVID prevalence estimates
277 align very well with that of the HPS survey.⁶ Finally, COVID mortality has been shown to
278 be higher among men (versus women), older (versus younger) people, non-Hispanic
279 Black and Hispanic people (versus non-Hispanic White people) and unvaccinated
280 (versus vaccinated) people^{31–34}, and estimates of the prevalence of long COVID may be
281 impacted by selection of people who survived COVID, if people who died would have
282 been more likely to go on to develop long COVID (survivorship bias).

283

284 Strengths of our study include the representative and probability-based design of the
285 survey, the ability for the survey to reflect outcomes among those who do not access
286 the healthcare system for their COVID infection(s) or long COVID, and the use of similar
287 questions to allow triangulation with other important data sources such as national
288 estimates of long COVID in the UK.

289

290 **Conclusions and Public Health Implications**

291 In a national population-representative sample, we observed a very high burden of long
292 COVID and estimated 7.3% of US residents aged 18 years or older (about 18 million
293 adults) had symptoms of long COVID during the two week study period ending July 2,
294 2022. Our estimate is more than double that of the UK (7.3% versus 2.8%), estimated
295 using a similar methodology, although the UK estimate is for those 2+ years of age. The
296 higher prevalence of long COVID among females relative to males in our study, is not
297 attributable to gender differences in cumulative incidence of prior COVID infections.
298 These differences are important areas of investigation for future research. We found

299 that the duration of long COVID symptoms extends to more than 12 months for many
300 people, but that the impact of long COVID on daily living decreases with time since the
301 most recent infection, suggesting possible improvement in long COVID symptoms over
302 time. Our findings underscore the importance of using a nationally-representative
303 sample to obtain estimates of disease burden when passive surveillance cannot. Such
304 approaches may be helpful for current and future infectious disease outbreaks and
305 pandemics.

306

307

308

309

310 **Tables and Figures**

311

Table 1. Prevalence and characteristics of US adults with COVID more than one month ago and long COVID, July 2022 - Among Wtd N = 3042 Respondents

Prevalence of Long COVID Among All Respondent (with or without COVID)							
	Total	Long COVID	Crude Prevalence of Long COVID % (95% CI)	Age and sex direct-standardized prevalence of long COVID* % (95% CI)	Crude prevalence ratio (PR) PR (95% CI)	Adjusted prevalence ratio (aPR)** aPR (95% CI)	Estimated Number with Long COVID
	Weighted N (%)	Weighted N (%)					
Total	3,042 (100.0)	222 (100.0)	7.3 (6.1, 8.5)				18,533,864
Age							
18-24	365 (12.0)	17 (7.8)	4.8 (0.9, 8.6)	4.4 (1.8 - 10.0)	0.45 (0.27, 0.76)	0.50 (0.30, 0.84)	1,445,641
25-34	547 (18.0)	58 (26.1)	10.6 (6.6, 14.6)	10.0 (6.8 - 14.6)	Ref	Ref	4,837,339
35-44	495 (16.3)	43 (19.1)	8.6 (5.3, 11.9)	9.0 (6.1 - 13.1)	0.81 (0.56, 1.18)	0.87 (0.60, 1.26)	3,539,968
45-54	498 (16.4)	37 (16.5)	7.4 (4.6, 10.2)	7.4 (5.1 - 10.7)	0.70 (0.47, 1.03)	0.72 (0.49, 1.07)	3,058,088
55-64	508 (16.7)	41 (18.2)	8.0 (5.5, 10.5)	8.3 (6.0 - 11.2)	0.75 (0.51, 1.10)	0.80 (0.55, 1.18)	3,373,163
65+	629 (20.7)	27 (12.2)	4.3 (3.0, 5.6)	4.2 (3.0 - 5.8)	0.41 (0.26, 0.63)	0.43 (0.27, 0.66)	2,261,131
Gender							
Male	1,443 (47.4)	72 (32.4)	5.0 (3.6, 6.3)	5.0 (3.8 - 6.5)	Ref	Ref	6,004,972
Female	1,516 (49.8)	144 (64.8)	9.5 (7.5, 11.5)	9.4 (7.7 - 11.6)	1.90 (1.45, 2.50)	1.84 (1.40, 2.42)	12,009,944

Non-binary***	82 (2.7)	6 (2.8)	7.4 (0.0, 17.2)	6.3 (2.1 - 17.6)	1.49 (0.67, 3.30)	1.45 (0.66, 3.21)	518,948
Race/Ethnicity							
Black NH	350 (11.5)	19 (8.4)	5.3 (2.1, 8.5)	5.2 (2.9 - 9.3)	0.64 (0.40, 1.03)	0.60 (0.38, 0.96)	1,556,845
White NH	1,794 (59.0)	148 (66.8)	8.3 (6.8, 9.8)	8.7 (7.1 - 10.7)	Ref	Ref	12,380,621
Hispanic	460 (15.1)	22 (9.7)	4.7 (1.3, 8.2)	5.7 (2.9 - 11.0)	0.57 (0.37, 0.88)	0.57 (0.37, 0.89)	1,797,785
Asian/Pacific Islander	171 (5.6)	7 (3.2)	4.2 (0.0, 9.4)	1.4 (0.3 - 5.9)	0.51 (0.25, 1.06)	0.44 (0.21, 0.93)	593,084
Other	268 (8.8)	26 (11.8)	9.8 (4.4, 15.2)	11.3 (6.8 - 18.3)	1.18 (0.80, 1.76)	1.23 (0.82, 1.86)	2,186,996
Education							
Some college, college graduate or above	1,859 (61.1)	138 (61.9)	7.4 (6.0, 8.8)	6.6 (4.9 - 8.9)	1.04 (0.80, 1.34)	1.08 (0.83, 1.41)	11,472,462
High school or below	1,183 (38.9)	85 (38.1)	7.2 (4.9, 9.4)	7.6 (6.2 - 9.2)	Ref	Ref	7,061,402
Household income							
Below 20K	561 (18.4)	34 (15.4)	6.1 (3.2, 9.0)	5.8 (3.7 - 9.1)	0.88 (0.55, 1.39)	0.86 (0.54, 1.38)	2,854,215
20,001 - 60,000	941 (30.9)	83 (37.2)	8.8 (6.3, 11.3)	8.8 (6.6 - 11.6)	1.26 (0.85, 1.86)	1.13 (0.76, 1.68)	6,894,598
60,001 - 100,000	568 (18.7)	48 (21.8)	8.5 (5.8, 11.3)	8.5 (6.1 - 11.7)	1.22 (0.80, 1.88)	1.15 (0.75, 1.76)	4,040,382
Above 100,000	460 (15.1)	32 (14.4)	7.0 (4.2, 9.7)	7.1 (4.7 - 10.4)	Ref	Ref	2,668,876
Prefer not to answer	511 (16.8)	25 (11.1)	4.8 (2.4, 7.3)	4.8 (2.9 - 7.8)	0.69 (0.42, 1.15)	0.75 (0.45, 1.25)	2,057,259
Employed July 2022							
Yes	1,472 (48.4)	123 (55.3)	8.3 (6.5, 10.2)	8.9 (7.2 - 11.0)	1.32 (1.02, 1.70)	1.34 (1.02, 1.76)	10,249,227
No/DK	1,570 (51.6)	99 (44.7)	6.3 (4.8, 7.9)	7.0 (5.2 - 9.5)	Ref	Ref	8,284,637
Geographic region							
Northeast	541 (17.8)	29 (13.2)	5.4 (3.4, 7.5)	5.6 (3.9 - 8.2)	Ref	Ref	2,446,470

South	1,153 (37.9)	92 (41.5)	8.0 (6.1, 10.0)	7.8 (6.1 - 9.8)	1.47 (0.99, 2.20)	1.40 (0.94, 2.09)	7,691,554
Midwest	630 (20.7)	52 (23.6)	8.3 (5.5, 11.2)	7.6 (5.3 - 10.8)	1.53 (0.99, 2.37)	1.52 (0.98, 2.35)	4,373,992
West	718 (23.6)	48 (21.6)	6.7 (3.8, 9.6)	6.5 (4.3 - 9.9)	1.23 (0.79, 1.92)	1.23 (0.79, 1.91)	4,003,315
Current vaccination status							
Boosted at least once	1,610 (52.9)	86 (38.7)	5.3 (4.0, 6.7)	5.8 (4.4 - 7.7)	Ref	Ref	7,172,606
Fully vaccinated not boosted	476 (15.6)	49 (22.2)	10.4 (6.6, 14.1)	9.8 (6.8 - 13.8)	1.94 (1.39, 2.71)	1.67 (1.19, 2.34)	4,114,518
Not vaccinated	957 (31.5)	87 (39.2)	9.1 (6.6, 11.6)	8.5 (6.4 - 11.3)	1.71 (1.28, 2.27)	1.41 (1.05, 1.91)	7,265,275
Timing of Most Recent COVID infection							
Never	1438 (47.3)	NA	NA	NA	NA	NA	NA
Within the last month	568 (18.7)	NA	NA	NA	NA	NA	NA
1-3 months ago	138 (4.5)	18 (8.2)	13.3 (6.9, 19.6)	14.1 (8.9 - 21.0)	0.50 (0.31, 0.80)	0.48 (0.30, 0.78)	1,519,777
3-6 months ago	266 (8.7)	77 (34.8)	29.1 (21.8, 36.4)	29.0 (22.8 - 36.0)	1.09 (0.83, 1.45)	1.07 (0.81, 1.42)	6,449,785
6-12 months ago	219 (7.2)	60 (27.1)	27.5 (19.3, 35.6)	26.7 (19.8 - 34.9)	1.03 (0.77, 1.40)	0.96 (0.71, 1.30)	5,022,677
>12 months ago	242 (8.0)	64 (28.9)	26.6 (19.7, 33.4)	26.5 (19.7 - 34.5)	Ref	Ref	5,356,287
Dont know	171 (5.6)	2 (0.9)	1.2 (0.0, 2.8)	1.5 (0.3 - 8.1)	0.05 (0.01, 0.18)	0.05 (0.01, 0.18)	166,805
Comorbidities							
Yes	1,104 (36.3)	96 (43.3)	8.7 (6.6, 10.8)	10.3 (7.8 - 13.4)	1.34 (1.04, 1.73)	1.55 (1.19, 2.00)	8,025,163
No	1,938 (63.7)	126 (56.7)	6.5 (5.0, 8.0)	6.1 (4.8 - 7.6)	Ref	Ref	10,508,701
Insured July 2022							

Yes	2,398 (78.8)	190 (85.7)	7.9 (6.5, 9.4)	8.0 (6.6 - 9.6)	1.61 (1.11, 2.31)	1.93 (1.33, 2.80)	15,883,522
No/DNK	644 (21.2)	32 (14.3)	4.9 (2.6, 7.3)	4.3 (2.7 - 6.8)	Ref	Ref	2,650,343
*Direct standardized for the age and sex groupings in the 2020 US census							
**Model adjusted for sex and age							
***Estimates are adjusted for age only							

312

Table 2. Prevalence and characteristics of US adults with reduced ability to carry out daily activities among those with long COVID, July 2022

	Total Long COVID Weighted N (%)	Reduce Ability to Carry Out Daily Activities			Crude prevalence ratio (PR) for any reduced ability (A lot vs A little, Not At All)	Adjusted prevalence ratio (aPR)*
		Yes, a lot Weighted N = 56	Yes, a little Weighted N = 110	Not at all Weighted N = 56	PR (95% CI)	aPR (95% CI)
Total	222 (100.0)	25.3 (18.2, 32.4)	49.6 (40.9, 58.3)	25.1 (17.6, 32.6)		
Estimated Number of US Residents	18,533,864	4,689,068	9,192,797	4,652,000		
Age						
18-34	75 (33.9)	19.3 (5.7, 32.9)	58.7 (41.1, 76.3)	22.0 (7.2, 36.8)	Ref	Ref
35-49	60 (27.0)	20.8 (7.4, 34.2)	51.1 (34.1, 68.2)	28.0 (13.1, 42.9)	1.08 (0.55, 2.12)	1.05 (0.53, 2.09)
50+	87 (39.1)	33.6 (23.9, 43.2)	40.7 (30.5, 50.9)	25.7 (15.9, 35.6)	1.74 (1.01, 3.01)	1.70 (0.98, 2.97)
Gender						
Male	72 (32.4)	25.5 (14.5, 36.5)	47.2 (33.4, 60.9)	27.3 (14.7, 39.9)	Ref	Ref

Female	144 (64.8)	25.7 (16.5, 35.0)	50.1 (38.9, 61.2)	24.2 (14.7, 33.7)	1.01 (0.62, 1.63)	1.06 (0.66, 1.73)
Non-binary**	6 (2.8)	12.3 (0.0, 39.5)	68.0 (18.1, 100.0)	19.7 (0.0, 54.8)	0.48 (0.06, 4.14)	0.58 (0.06, 5.69)
Race/Ethnicity						
Black NH	19 (8.4)	7.4 (0.0, 21.6)	52.3 (21.5, 83.1)	40.3 (10.3, 70.4)	0.23 (0.05, 1.17)	0.23 (0.04, 1.15)
White NH	148 (66.8)	32.0 (23.2, 40.9)	45.4 (36.0, 54.8)	22.6 (14.7, 30.5)	Ref	Ref
Hispanic	22 (9.7)	3.6 (0.0, 10.9)	45.1 (7.1, 83.0)	51.3 (13.8, 88.9)	0.11 (0.01, 1.01)	0.12 (0.01, 1.04)
Other/Asian/Pacific Islander	33 (15.1)	19.5 (1.8, 37.1)	69.9 (48.5, 91.3)	10.7 (0.0, 23.9)	0.61 (0.29, 1.26)	0.68 (0.32, 1.48)
Education						
Some college, college graduate or above	138 (61.9)	24.0 (16.5, 31.4)	48.1 (38.4, 57.8)	27.9 (18.8, 37.1)	0.87 (0.55, 1.38)	0.75 (0.47, 1.19)
High school or below	85 (38.1)	27.5 (13.4, 41.5)	52.1 (35.7, 68.5)	20.5 (8.0, 33.0)	Ref	Ref
Household income						
Below 60K	117 (52.6)	32.9 (21.4, 44.4)	51.9 (39.2, 64.5)	15.2 (6.7, 23.8)	1.86 (1.09, 3.19)	2.22 (1.31, 3.78)
Above 60K	81 (36.2)	17.6 (9.4, 25.9)	46.9 (33.7, 60.1)	35.5 (22.9, 48.1)	Ref	Ref
Prefer not to answer	25 (11.1)	14.3 (0.8, 27.9)	47.8 (21.9, 73.8)	37.9 (10.4, 65.3)	0.81 (0.28, 2.38)	0.74 (0.25, 2.14)
Employed July 2022						
Yes	123 (55.3)	16.4 (9.1, 23.7)	59.1 (48.0, 70.3)	24.5 (14.8, 34.2)	0.45 (0.28, 0.73)	0.48 (0.29, 0.79)
No/DK	99 (44.7)	36.3 (24.1, 48.6)	37.9 (25.2, 50.5)	25.8 (14.1, 37.5)	Ref	Ref
Vaccination status						
Boosted at least once	86 (38.7)	24.8 (15.1, 34.4)	47.2 (34.3, 60.1)	28.1 (16.0, 40.1)	Ref	Ref
Fully vaccinated not boosted	49 (22.2)	26.4 (8.9, 43.8)	53.8 (34.3, 73.2)	19.9 (4.5, 35.3)	1.06 (0.59, 1.93)	1.05 (0.57, 1.91)
Not vaccinated	87 (39.2)	25.2 (13.6, 36.9)	49.7 (35.1, 64.2)	25.1 (13.1, 37.1)	1.02 (0.61, 1.71)	1.17 (0.69, 2.00)
Current Number of COVID infections						
One	176 (79.2)	25.7 (18.2, 33.2)	46.3 (36.8, 55.8)	27.9 (19.3, 36.6)	Ref	Ref

More than one	46 (20.8)	23.7 (5.3, 42.2)	62.1 (41.8, 82.3)	14.2 (2.0, 26.4)	0.92 (0.52, 1.64)	1.06 (0.58, 1.95)
Timing of past COVID infections						
1-6 months ago (including DNK (wtd N = 3))	98 (44.0)	30.2 (18.5, 41.8)	52.3 (39.3, 65.4)	17.5 (7.7, 27.2)	Ref	Ref
6-12 months ago	60 (27.1)	24.2 (10.4, 38.1)	40.6 (22.7, 58.5)	35.2 (17.7, 52.6)	0.80 (0.47, 1.38)	0.80 (0.47, 1.36)
>12 months ago	64 (28.9)	18.9 (8.6, 29.2)	53.9 (39.2, 68.6)	27.2 (14.7, 39.7)	0.63 (0.35, 1.13)	0.52 (0.29, 0.94)
Hybrid Immunity July 2022						
Vaccine- and infection-induced	135 (60.8)	25.3 (16.5, 34.2)	49.6 (38.7, 60.4)	25.1 (15.5, 34.7)	Ref	Ref
Infection-induced only	87 (39.2)	25.2 (13.6, 36.9)	49.7 (35.1, 64.2)	25.1 (13.1, 37.1)	1.00 (0.63, 1.58)	1.15 (0.71, 1.87)
Comorbidities						
Yes	96 (43.3)	27.4 (16.5, 38.4)	47.1 (34.6, 59.7)	25.4 (14.5, 36.3)	1.16 (0.74, 1.82)	1.08 (0.67, 1.73)
No	126 (56.7)	23.7 (14.5, 32.8)	51.5 (39.5, 63.5)	24.8 (14.6, 35.1)	Ref	Ref
Insured July 2022						
Yes	190 (85.7)	27.7 (19.8, 35.7)	51.4 (42.1, 60.7)	20.8 (13.7, 28.0)	2.60 (0.93, 7.28)	2.57 (0.88, 7.54)
No/DNK	32 (14.3)	10.7 (0.0, 22.3)	38.9 (16.4, 61.4)	50.4 (26.5, 74.4)	Ref	Ref
*Model adjusted for gender and age						
**Estimates are adjusted for age only						

313

Table 3. Prevalence and characteristics of US adults with COVID and prevalence of long COVID among US adults with COVID, July 2022		
Prevalence of Ever COVID as of July 2022		

	Total	Had COVID as of July 2022	Crude Prevalence of COVID % (95% CI)	Age and sex direct-standardized prevalence of COVID* % (95% CI)	Crude prevalence ratio (PR) PR (95% CI)	Adjusted prevalence ratio (aPR)** aPR (95% CI)
	Weighted N (%)	Weighted N (%)				
Total	3,042 (100.0)	1604 (100.0)	52.7 (50.2, 55.2)			
Age						
18-24	365 (12.0)	235 (14.6)	64.4 (54.8, 74.0)	60.8 (51.9 - 69.0)	0.97 (0.88, 1.07)	0.98 (0.89, 1.07)
25-34	547 (18.0)	364 (22.7)	66.5 (60.1, 72.8)	66.0 (59.0 - 72.4)	Ref	Ref
35-44	495 (16.3)	265 (16.5)	53.4 (47.0, 59.9)	51.5 (44.9 - 58.0)	0.80 (0.73, 0.89)	0.81 (0.74, 0.90)
45-54	498 (16.4)	237 (14.8)	47.6 (41.3, 53.8)	47.6 (41.4 - 54.0)	0.72 (0.64, 0.80)	0.72 (0.65, 0.81)
55-64	508 (16.7)	250 (15.6)	49.2 (44.4, 54.1)	49.0 (44.1 - 53.8)	0.74 (0.67, 0.82)	0.74 (0.67, 0.83)
65+	629 (20.7)	254 (15.8)	40.3 (37.3, 43.3)	39.6 (36.6 - 42.7)	0.61 (0.54, 0.68)	0.61 (0.55, 0.68)
Gender						
Male	1,443 (47.4)	813 (50.7)	56.3 (52.5, 60.2)	56.8 (53.2 - 60.4)	Ref	Ref
Female	1,516 (49.8)	726 (45.3)	47.9 (44.6, 51.2)	47.8 (44.5 - 51.1)	0.85 (0.79, 0.91)	0.84 (0.78, 0.89)
Non-binary***	82 (2.7)	65 (4.0)	78.5 (66.4, 90.6)	77.1 (64.1 - 86.4)	1.39 (1.23, 1.57)	1.22 (1.09, 1.36)
Race/Ethnicity						
Black NH	350 (11.5)	169 (10.5)	48.2 (40.7, 55.6)	44.9 (37.9 - 52.1)	0.90 (0.80, 1.02)	0.81 (0.72, 0.91)
White NH	1,794 (59.0)	922 (57.5)	51.4 (48.9, 53.9)	53.2 (50.4 - 55.9)	Ref	Ref
Hispanic	460 (15.1)	307 (19.2)	66.8 (58.6, 75.0)	60.7 (52.7 - 68.1)	1.29 (1.19, 1.40)	1.16 (1.07, 1.25)
Asian/Pacific Islander	171 (5.6)	75 (4.6)	43.7 (28.9, 58.5)	34.6 (24.3 - 46.5)	0.78 (0.64, 0.95)	0.69 (0.57, 0.84)
Other	268 (8.8)	131 (8.2)	48.8 (39.3, 58.3)	50.7 (40.7 - 60.6)	0.90 (0.78, 1.04)	0.88 (0.76, 1.02)
Education						

Some college, college graduate or above	1,859 (61.1)	942 (58.7)	50.7 (48.0, 53.3)	53.4 (49.0 - 57.7)	Ref	Ref
High school or below	1,183 (38.9)	662 (41.3)	56.0 (51.2, 60.8)	51.5 (48.5 - 54.4)	1.10 (1.03, 1.18)	1.04 (0.97, 1.11)
Household income						
Below 20K	561 (18.4)	327 (20.4)	58.3 (51.1, 65.6)	54.2 (47.9 - 60.2)	0.98 (0.88, 1.08)	0.98 (0.89, 1.08)
20,001 - 60,000	941 (30.9)	474 (29.5)	50.3 (45.9, 54.7)	48.1 (43.7 - 52.6)	0.84 (0.76, 0.93)	0.84 (0.77, 0.93)
60,001 - 100,000	568 (18.7)	301 (18.8)	53.0 (48.0, 58.0)	54.1 (48.9 - 59.2)	0.89 (0.80, 0.99)	0.91 (0.82, 1.01)
Above 100,000	460 (15.1)	275 (17.1)	59.8 (54.4, 65.1)	59.1 (53.3 - 64.6)	Ref	Ref
Prefer not to answer	511 (16.8)	227 (14.2)	44.4 (38.8, 50.0)	45.7 (38.5 - 53.0)	0.74 (0.66, 0.84)	0.80 (0.71, 0.89)
Employed July 2022						
Yes	1,472 (48.4)	905 (56.4)	61.5 (57.9, 65.1)	57.7 (54.3 - 61.0)	1.41 (1.32, 1.52)	1.31 (1.21, 1.41)
No/DK	1,570 (51.6)	699 (43.6)	44.5 (41.2, 47.7)	43.5 (39.0 - 48.0)	Ref	Ref
Geographic region						
Northeast	541 (17.8)	307 (19.1)	56.6 (51.4, 61.9)	56.3 (51.4 - 61.2)	Ref	Ref
South	1,153 (37.9)	603 (37.6)	52.3 (48.4, 56.2)	51.5 (47.7 - 55.3)	0.92 (0.84, 1.01)	0.94 (0.86, 1.02)
Midwest	630 (20.7)	323 (20.1)	51.3 (46.2, 56.5)	50.7 (45.3 - 56.1)	0.91 (0.81, 1.01)	0.95 (0.86, 1.05)
West	718 (23.6)	371 (23.2)	51.7 (45.6, 57.8)	51.0 (45.3 - 56.6)	0.91 (0.82, 1.01)	0.96 (0.87, 1.06)
Current vaccination status						
Boosted at least once	1,610 (52.9)	849 (52.9)	52.7 (49.4, 56.1)	53.2 (49.8 - 56.5)	Ref	Ref
Fully vaccinated not boosted	476 (15.6)	230 (14.3)	48.3 (42.3, 54.3)	47.4 (41.0 - 53.9)	0.92 (0.83, 1.02)	0.90 (0.81, 0.99)
Not vaccinated	957 (31.5)	525 (32.8)	54.9 (50.1, 59.7)	53.2 (48.7 - 57.8)	1.04 (0.97, 1.12)	0.94 (0.88, 1.01)
Comorbidities						
Yes	1,104 (36.3)	643 (40.1)	58.3 (54.2, 62.4)	59.8 (55.8 - 63.7)	1.18 (1.10, 1.26)	1.27 (1.20, 1.36)

No	1,938 (63.7)	961 (59.9)	49.6 (46.5, 52.6)	48.4 (45.4 - 51.5)	Ref	Ref
Insured July 2022						
Yes	2,398 (78.8)	1,277 (79.6)	53.3 (50.5, 56.0)	53.7 (51.1 - 56.3)	1.05 (0.96, 1.14)	1.21 (1.12, 1.31)
No/DNK	644 (21.2)	327 (20.4)	50.7 (44.8, 56.6)	46.9 (41.1 - 52.8)	Ref	Ref
*Direct standardized for the age and sex groupings in the 2020 US census						
**Model adjusted for gender and age						
***Estimates are adjusted for age only						

314

Supp Table 1. Prevalence and characteristics of US adults with COVID and long COVID, July 2022 - Among Wtd N = 3042 Respondents						
	Prevalence of Long COVID			Prevalence of Ever COVID as of July 2022		
	Long COVID	Crude Prevalence of Long COVID % (95% CI)	Adjusted prevalence ratio (aPR)*	Had COVID as of July 2022	Crude Prevalence of COVID % (95% CI)	Adjusted Prevalence Ratio (aPR)*
	Weighted N (%)		aPR (95% CI)	Weighted N (%)		aPR (95% CI)
Total	222 (100.0)	7.3 (6.1, 8.5)		1604 (100.0)	52.7 (50.2, 55.2)	
Age						
18-24	17 (7.8)	4.8 (0.9, 8.6)	0.47 (0.26, 0.84)	235 (14.6)	64.4 (54.8, 74.0)	0.98 (0.91, 1.06)
25-34	58 (26.1)	10.6 (6.6, 14.6)	Ref	364 (22.7)	66.5 (60.1, 72.8)	Ref
35-44	43 (19.1)	8.6 (5.3, 11.9)	0.78 (0.54, 1.14)	265 (16.5)	53.4 (47.0, 59.9)	0.77 (0.70, 0.85)

45-54	37 (16.5)	7.4 (4.6, 10.2)	0.60 (0.40, 0.89)	237 (14.8)	47.6 (41.3, 53.8)	0.68 (0.62, 0.76)
55-64	41 (18.2)	8.0 (5.5, 10.5)	0.62 (0.42, 0.93)	250 (15.6)	49.2 (44.4, 54.1)	0.68 (0.62, 0.75)
65+	27 (12.2)	4.3 (3.0, 5.6)	0.33 (0.20, 0.52)	254 (15.8)	40.3 (37.3, 43.3)	0.57 (0.51, 0.64)
Gender						
Male	72 (32.4)	5.0 (3.6, 6.3)	Ref	813 (50.7)	56.3 (52.5, 60.2)	Ref
Female	144 (64.8)	9.5 (7.5, 11.5)	1.80 (1.37, 2.37)	726 (45.3)	47.9 (44.6, 51.2)	0.86 (0.81, 0.92)
Non-binary****	6 (2.8)	7.4 (0.0, 17.2)	NA	65 (4.0)	78.5 (66.4, 90.6)	
Race/Ethnicity						
Black NH	19 (8.4)	5.3 (2.1, 8.5)	0.61 (0.39, 0.96)	169 (10.5)	48.2 (40.7, 55.6)	0.84 (0.74, 0.94)
White NH	148 (66.8)	8.3 (6.8, 9.8)	Ref	922 (57.5)	51.4 (48.9, 53.9)	Ref
Hispanic	22 (9.7)	4.7 (1.3, 8.2)	0.68 (0.42, 1.08)	307 (19.2)	66.8 (58.6, 75.0)	1.14 (1.06, 1.23)
Asian/Pacific Islander	7 (3.2)	4.2 (0.0, 9.4)	0.18 (0.05, 0.60)	75 (4.6)	43.7 (28.9, 58.5)	0.72 (0.59, 0.87)
Other	26 (11.8)	9.8 (4.4, 15.2)	1.41 (0.95, 2.09)	131 (8.2)	48.8 (39.3, 58.3)	0.92 (0.80, 1.07)
Education						
Some college, college graduate or above	138 (61.9)	7.4 (6.0, 8.8)		942 (58.7)	50.7 (48.0, 53.3)	
High school or below	85 (38.1)	7.2 (4.9, 9.4)		662 (41.3)	56.0 (51.2, 60.8)	
Household income						
Below 20K	34 (15.4)	6.1 (3.2, 9.0)		327 (20.4)	58.3 (51.1, 65.6)	0.93 (0.86, 1.02)
20,001 - 60,000	83 (37.2)	8.8 (6.3, 11.3)		474 (29.5)	50.3 (45.9, 54.7)	0.84 (0.77, 0.92)
60,001 - 100,000	48 (21.8)	8.5 (5.8, 11.3)		301 (18.8)	53.0 (48.0, 58.0)	0.90 (0.82, 0.98)
Above 100,000	32 (14.4)	7.0 (4.2, 9.7)		275 (17.1)	59.8 (54.4, 65.1)	Ref
Prefer not to answer	25 (11.1)	4.8 (2.4, 7.3)		227 (14.2)	44.4 (38.8, 50.0)	0.87 (0.77, 0.98)
Current vaccination status						

Boosted	86 (38.7)	5.3 (4.0, 6.7)		Ref 849 (52.9)	52.7 (49.4, 56.1)	
Fully vaccinated not boosted	49 (22.2)	10.4 (6.6, 14.1)	1.76 (1.26, 2.46)	230 (14.3)	48.3 (42.3, 54.3)	
Not vaccinated	87 (39.2)	9.1 (6.6, 11.6)	1.53 (1.12, 2.09)	525 (32.8)	54.9 (50.1, 59.7)	
Comorbidities						
Yes	96 (43.3)	8.7 (6.6, 10.8)	1.64 (1.26, 2.13)	643 (40.1)	58.3 (54.2, 62.4)	1.24 (1.17, 1.32)
No	126 (56.7)	6.5 (5.0, 8.0)		Ref 961 (59.9)	49.6 (46.5, 52.6)	Ref
Insured July 2022						
Yes	190 (85.7)	7.9 (6.5, 9.4)	1.87 (1.28, 2.75)	1,277 (79.6)	53.3 (50.5, 56.0)	
No/DNK	32 (14.3)	4.9 (2.6, 7.3)		Ref 327 (20.4)	50.7 (44.8, 56.6)	
*Model adjusted for all variables included						

315

317 **Funding:**

318 Funding for this project was provided by the CUNY Institute for Implementation Science
319 in Population Health (cunyisph.org).

320 **Acknowledgements:**

321 The authors wish to acknowledge the survey participants and Consensus Strategies for
322 completing survey sampling and data collection.

323

324

325
326
327

References

- 328 1. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the
329 UK - Office for National Statistics.
330 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditi>
331 [onsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditi)
332 [19infectionintheuk/6may2022](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditi).
- 333 2. Bull-Otterson, L. Post-COVID Conditions Among Adult COVID-19 Survivors Aged
334 18–64 and ≥65 Years — United States, March 2020–November 2021. *MMWR*
335 *Morb. Mortal. Wkly. Rep.* **71**, (2022).
- 336 3. Saydah, S. H., Brooks, J. T. & Jackson, B. R. Surveillance for Post-COVID
337 Conditions Is Necessary: Addressing the Challenges with Multiple Approaches. *J.*
338 *Gen. Intern. Med.* **37**, 1786–1788 (2022).
- 339 4. Clarke, K. E. N. *et al.* Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies
340 - United States, September 2021-February 2022. *MMWR Morb. Mortal. Wkly. Rep.*
341 **71**, 606–608 (2022).
- 342 5. Chen, C. *et al.* Global Prevalence of Post COVID-19 Condition or Long COVID: A
343 Meta-Analysis and Systematic Review. *J. Infect. Dis.* (2022)
344 [doi:10.1093/infdis/jiac136](https://doi.org/10.1093/infdis/jiac136).
- 345 6. Long COVID. <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm> (2022).
- 346 7. Wanga, V. *et al.* Long-Term Symptoms Among Adults Tested for SARS-CoV-2 -
347 United States, January 2020-April 2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**,
348 1235–1241 (2021).
- 349 8. CDC. COVID data tracker. *Centers for Disease Control and Prevention*

- 350 <https://covid.cdc.gov/covid-data-tracker/> (2020).
- 351 9. Ayoubkhani, D., King, S. & Pawelek, P. Prevalence of ongoing symptoms following
352 coronavirus (COVID-19) infection in the UK - Office for National Statistics.
353 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditi
354 onsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid
355 19infectionintheuk/7july2022](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7july2022) (2022).
- 356 10. Thompson, E. J. *et al.* Long COVID burden and risk factors in 10 UK longitudinal
357 studies and electronic health records. *Nat. Commun.* **13**, 3528 (2022).
- 358 11. Fernández-de-Las-Peñas, C. *et al.* Symptoms Experienced at the Acute Phase of
359 SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The
360 LONG-COVID-EXP-CM Multicenter Study. *Int. J. Infect. Dis.* (2022).
- 361 12. Yomogida, K. *et al.* Post-acute sequelae of SARS-CoV-2 infection among adults
362 aged ≥ 18 years - Long Beach, California, April 1-December 10, 2020. *MMWR Morb.
363 Mortal. Wkly. Rep.* **70**, 1274–1277 (2021).
- 364 13. Sudre, C. H. *et al.* Attributes and predictors of long COVID. *Nat. Med.* **27**, 626–631
365 (2021).
- 366 14. Cristillo, V. *et al.* Premorbid vulnerability and disease severity impact on Long-
367 COVID cognitive impairment. *Ageing Clin. Exp. Res.* **34**, 257–260 (2022).
- 368 15. Behnood, S. A. *et al.* Persistent symptoms following SARS-CoV-2 infection
369 amongst children and young people: A meta-analysis of controlled and uncontrolled
370 studies. *Journal of Infection* vol. 84 158–170 (2022).
- 371 16. Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of
372 the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy,

- 373 effectiveness and escape. *Nat. Rev. Immunol.* **21**, 626–636 (2021).
- 374 17. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529)
375 Variant. *N. Engl. J. Med.* **386**, 1532–1546 (2022).
- 376 18. Abu-Raddad, L. J. *et al.* Effect of mRNA Vaccine Boosters against SARS-CoV-2
377 Omicron Infection in Qatar. *N. Engl. J. Med.* **386**, 1804–1816 (2022).
- 378 19. Altarawneh, H. N. *et al.* Effects of Previous Infection and Vaccination on
379 Symptomatic Omicron Infections. *N. Engl. J. Med.* **387**, 21–34 (2022).
- 380 20. Tan, S. T. *et al.* Infectiousness of SARS-CoV-2 breakthrough infections and
381 reinfections during the Omicron wave. *bioRxiv* (2022)
382 doi:10.1101/2022.08.08.22278547.
- 383 21. Mahase, E. Covid-19: Vaccinated people are less likely to get long covid, review
384 finds. *BMJ* **376**, o407 (2022).
- 385 22. Patient Safety Learning. The effectiveness of vaccination against Long Covid: A
386 rapid evidence briefing (February 2022). *Patient Safety Learning - the hub*
387 [https://www.pslhub.org/learn/coronavirus-covid19/data-and-statistics/the-](https://www.pslhub.org/learn/coronavirus-covid19/data-and-statistics/the-effectiveness-of-vaccination-against-long-covid-a-rapid-evidence-briefing-february-2022-r6159/)
388 [effectiveness-of-vaccination-against-long-covid-a-rapid-evidence-briefing-february-](https://www.pslhub.org/learn/coronavirus-covid19/data-and-statistics/the-effectiveness-of-vaccination-against-long-covid-a-rapid-evidence-briefing-february-2022-r6159/)
389 [2022-r6159/](https://www.pslhub.org/learn/coronavirus-covid19/data-and-statistics/the-effectiveness-of-vaccination-against-long-covid-a-rapid-evidence-briefing-february-2022-r6159/) (2022).
- 390 23. United States Census Bureau. QuickFacts: United States.
- 391 24. CSTE Interim Position Statement: Update to COVID-19 Case Definition - Council of
392 State and Territorial Epidemiologists. [https://www.cste.org/news/520707/CSTE-](https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm)
393 [Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm](https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm).
- 394 25. Coronavirus (COVID-19) Infection Survey: methods and further information.
395 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditi>

- 396 onsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinfor
397 mation.
- 398 26. US Census Bureau. Population under age 18 declined last decade. (2022).
- 399 27. COVID-19 vaccine boosters administered per 100 people. *Our World in Data*
400 [https://ourworldindata.org/grapher/covid-vaccine-booster-doses-per-](https://ourworldindata.org/grapher/covid-vaccine-booster-doses-per-capita?country=USA~OWID_WRL~GBR)
401 [capita?country=USA~OWID_WRL~GBR](https://ourworldindata.org/grapher/covid-vaccine-booster-doses-per-capita?country=USA~OWID_WRL~GBR).
- 402 28. Thakur, B. *et al.* A systematic review and meta-analysis of geographic differences in
403 comorbidities and associated severity and mortality among individuals with COVID-
404 19. *Sci. Rep.* **11**, 8562 (2021).
- 405 29. Subramanian, A. *et al.* Symptoms and risk factors for long COVID in non-
406 hospitalized adults. *Nat. Med.* (2022) doi:10.1038/s41591-022-01909-w.
- 407 30. Carfi, A., Bernabei, R., Landi, F. & Gemelli Against COVID-19 Post-Acute Care
408 Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **324**,
409 603–605 (2020).
- 410 31. CDC. Risk for COVID-19 infection, hospitalization, and death by race/ethnicity.
411 *Centers for Disease Control and Prevention* [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html)
412 [ncov/covid-data/investigations-discovery/hospitalization-death-by-race-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html)
413 [ethnicity.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html) (2022).
- 414 32. Johnson, A. G. *et al.* COVID-19 Incidence and Death Rates Among Unvaccinated
415 and Fully Vaccinated Adults with and Without Booster Doses During Periods of
416 Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December
417 25, 2021. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 132–138 (2022).
- 418 33. Daniels, A. C. *et al.* Sex disparities in COVID-19 outcomes in the United States:

- 419 Quantifying and contextualizing variation. *Soc. Sci. Med.* **294**, 114716 (2022).
- 420 34. Aburto, J. M., Tilstra, A. M., Floridi, G. & Dowd, J. B. Significant impacts of the
- 421 COVID-19 pandemic on race/ethnic differences in US mortality. *Proc. Natl. Acad.*
- 422 *Sci. U. S. A.* **119**, e2205813119 (2022).

423
424

425 **Appendix 1 (Survey design)**

426 Sampling Frame. A sampling frame of 254,297,978 Residents of the United States
427 consisting of 105,469,157 mobile numbers with an additional 60,126,857 landlines. Two
428 stratified proportionate randomized population-based samples were drawn for this
429 study, n=90,000 mobile numbers and n=50,000 landlines. An National opt-in Online
430 Panel provided by Consensus Strategies was used in the study. A total sample of
431 n=3,042 was utilized with a +/- 3 percent margin of error. Data was collected June 30 -
432 July 2, 2022.

433
434 Multi-mode data collection design. Short message service (SMS) aka text messages
435 were sent using SMS platform. The respondents were sent a personalized first name
436 text message which included a link to the survey and an opt-out option. The
437 respondents had the option to reply to the SMS text with any queries. Data was verified
438 by IP address and scrubbed against the original survey sample.

439
440 Interactive voice response (IVR) aka robo-poll messages were sent to landlines. The
441 respondents were able to answer the survey questions using the touch tone keypad on
442 their phones.

443 The opt-in online panel was created by Consensus Strategies and participants were
444 paid an incentive to complete the surveys of up to \$2. Respondents were verified by
445 payment information.

446 Survey weighting. The survey was weighted using an iterative weighting method
447 (raking) to marginal proportions of race, ethnicity, age, self-identified sex, and education
448 by U.S. region. The samples (landline, online, mobile) were normalized at the region
449 level based on sex, age, gender, education, race and sample size then combined and
450 weighted back based on the proportion of the region to the overall population and the
451 other demographics. The sum of the weights equals the sample population (n=3,042).
452 Demographic weights were created based on the American Community Survey 5-year
453 estimates and [2020 US Census](#). The inference population is 254,297,978 million adult
454 residents.

455
456 Response rates. Our overall combined response rates across all modalities was 7.2%.
457 The response rate was 6.2% for random digit dial to landline, 0.9% for cell phone, and
458 86.5% for opt-in online panel. The response rate reflects the proportion of complete
459 respondents among eligible participants in the sampling frame. For context, we also
460 included response rates for the Household Pulse Survey (HPS), an online survey
461 sampling households from the Census Master Address File with an email or cell phone
462 number. While our response rates are comparable, the HPS methodology calculates the
463 response rate based on completes and sufficient partial interviews, compared to our
464 rates which are based on complete interviews (i.e., more conservative rates)

	<i>National COVID-19 Survey (June-July 2022)</i>	<i>HPS 202</i>	<i>HP S</i>	<i>HP S</i>	<i>HP S</i>	<i>HP S</i>
--	---	---------------------------	------------------------	------------------------	------------------------	------------------------

<i>Mode</i>	<i>Landline</i>	<i>Cell</i>	<i>Online opt-in panel</i>	<i>Combined</i>	<i>2 Jun 29-Jul 11</i>	<i>2022 Jun 1-Jul 13</i>	<i>2020 Week 1</i>	<i>2020 Week 2</i>	<i>2020 Week 3</i>
<i>RR</i>	6.2	0.9	86.5	7.2	5.7	6.2	3.8	1.3	2.3

465

466

467 **Appendix 2 (Survey questionnaire)**

468 ***Survey on recent COVID exposure, COVID infection, and testing behaviors in the***
 469 ***United States***

470

471 Hello, this is XYZ with a brief public policy survey. At no time will we try to sell you
 472 anything. We are just interested in your opinions, and you can drop out at any time.

473

474 To begin, what language would you like to take this survey in?

- 475 1. English
- 476 2. Español

477

478 **The following questions will ask about COVID exposure in the past 2 weeks**

479

480 1. In the past 2 weeks, have you experienced any COVID-like symptoms (e.g., 100
 481 degrees fever or higher, chills, cough, sore throat, fatigue, headache, shortness
 482 of breath, congestion or runny nose, muscle aches, loss of smell or taste,
 483 nausea, or diarrhea)?

- 484 a. Yes
- 485 b. No
- 486 c. Don't know/not sure

487

488 2. In the past 2 weeks, were you aware of an exposure you had to someone who
 489 had COVID-like symptoms or tested positive for COVID-19?

- 490 a. Yes

- 491 b. No
492 c. Don't know/not sure

493

494 **The following questions will ask about COVID testing in the past 2 weeks**

495

496 3. In the past 2 weeks, have you taken an at-home rapid test for COVID-19? (a
497 rapid at-home test allows you to collect your own sample and get results within
498 minutes at home)

- 499 a. Yes, Tested Positive
500 b. Yes, Tested Negative
501 c. No, I have not tested

502

503 4. In the past 2 weeks, have you taken a rapid antigen or PCR test for COVID-19
504 from a healthcare or testing provider?

- 505 a. Yes, Tested Positive
506 b. Yes, Tested Negative
507 c. No, I have not tested [skip to 6]

508

509 5. *If tested with a healthcare provider.* When you tested with a healthcare or testing
510 provider, which type of test did you receive?

- 511 a. Rapid test/point of care test
512 b. PCR test
513 c. Both
514 d. Not sure/don't know

515

516 6. Prior to June 15th 2022, did you ever have COVID-19 infection, either diagnosed
517 by a healthcare or testing provider, or based on a positive at-home rapid test?

- 518 a. Yes, once
519 b. Yes, more than once
520 c. No, but I am pretty sure that I had COVID
521 d. No, I don't think I have ever had COVID [skip to 8]
522 e. Don't know/not sure [skip to 8]

523

524 7. When was the last time you had COVID?

- 525 a. Within the last month (if you currently have COVID, choose
526 this option)
527 b. 1-3 months ago
528 c. 3-6 months ago
529 d. 6-12 months ago
530 e. >12 months ago

531 f. Don't know/not sure

532

533 **Long COVID**

534

535 8. Would you describe yourself as having 'long COVID', that is you experienced
536 symptoms such as fatigue, difficulty concentrating, shortness of breath more than
537 4 weeks after you first had COVID-19 that are not explained by something else?

538 a. Yes

539 b. No [skip to 10]

540 c. Don't know/not sure [skip to 10]

541

542 9. Does this reduce your ability to carry-out day-to-day activities compared with the
543 time before you had COVID-19?

544 a. Yes, a lot

545 b. Yes, a little

546 c. Not at all

547 d. Don't know/not sure

548

549 **Respondent Characteristics**

550

551 10. Do you currently have any kind of health care coverage, including health
552 insurance, prepaid plans such as HMOs, or government plans such as Medicaid
553 or Medicare, or Indian Health Service?

554 a. Yes

555 b. No

556 c. Don't know/not sure

557

558 11. Do you have any of the following conditions that could increase the severity of
559 COVID-19: cancer, diabetes, obesity, COPD or lung disease, liver disease, heart
560 disease, high blood pressure, a recent organ transplant, or an
561 immunodeficiency)?

562 a. Yes

563 b. No

564 c. Don't know/not sure

565

566 12. Have you been fully vaccinated against COVID-19? [Either 2 doses of mRNA
567 vaccine series (Moderna or Pfizer) or a single dose of Johnson and Johnson
568 COVID-19 vaccine]

569 a. Yes

570 b. No (go to 14)

- 571 c. Don't know/not sure (go to 14)
- 572
- 573 13. If you have been fully vaccinated, have you also received at least one
- 574 coronavirus booster?
- 575 a. Yes, more than 5 months ago
- 576 b. Yes, within the past 5 months
- 577 c. No
- 578
- 579 14. If not fully vaccinated OR not boosted: Do you plan to get a vaccine dose or
- 580 booster in the next two weeks?
- 581 a. Yes
- 582 b. No
- 583 c. Don't know/not sure
- 584
- 585 15. What is your age?
- 586 a. 18-24
- 587 b. 25-34
- 588 c. 35-44
- 589 d. 45-49
- 590 e. 50-54
- 591 f. 55-64
- 592 g. 65-74
- 593 h. 75 +
- 594
- 595 16. How do you currently identify your gender? Do you identify as ...
- 596 a. Male
- 597 b. Female
- 598 c. Gender non-binary
- 599 d. other
- 600
- 601 17. Which one of the following would you use to describe yourself ?
- 602 a. Latino/a, or of Hispanic or Spanish origin
- 603 b. White
- 604 c. Black or African American
- 605 d. Asian, Native Hawaiian or Other Pacific Islander
- 606 e. American Indian/Alaska Native
- 607 f. More than one race
- 608 g. other
- 609
- 610

- 611 18. What is the highest grade or year of school you completed?
612 a. Less than high school
613 b. Grade 12 or GED (High school graduate)
614 c. College 1 year to 3 years (Some college or technical school,
615 associate degree)
616 d. College 4 years or more (College graduate)

617
618

- 619 19. Are you currently employed for wages or salary?
620 a. Yes
621 b. No
622 c. Don't know/not sure

623

- 624 20. What is your household's annual income?
625 a. \$20,000 or less
626 b. Between \$20,001 - \$40,000
627 c. Between \$40,001 - \$60,000
628 d. Between \$60,001 - \$80,000
629 e. Between \$80,001 - \$100,000
630 f. Above \$100,000
631 g. Prefer not to answer
632 h. Don't know/not sure

633
634
635
636
637